Endo Pharmaceuticals has received approval for low testosterone treatment Fortesta.

The US Food and Drug Administration has given the drug its approval, and Fortesta has been scheduled for market introduction in early 2011.

Fortesta is a 2% testosterone transdermal gel for testosterone replacement therapy in male hypogonadism. It uses a metered dose-delivery system designed to permit accurate dose adjustment to individual patient requirements.

Endo, which reported sales worth $1.6bn in 2010, is expected to see a sales boost to approximately $2.3bn over the next fiscal year.